welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million
Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.

expertly curated content related to this topic
-
Robert Daniel Odze, MD, FRCPCRobert Daniel Odze is a Professor of Pat...
-
Family Help PolyposisThe family assistance polyposis coli eV ...
-
HELIOS Klinikum WuppertalCenter for Hereditary Tumor Di...
-
Todd SpurrierThe mission of DESTINATION X RIDE (DXR) ...
-
Thetis Pharmaceuticals Awarded Key Patent on HEALER TechnologyThetis Pharmaceuticals LLC, a privately-...
-
Ohio State University HospitalsPatient Resources: The Ja...